



MOSt Signature

Model Portfolio

April 2025







Portfolio Investment Characteristics

- · A dynamic portfolio with a mix of Large and Mid-Caps
- Large Caps & Mid Caps with 5% weight each.
- Focused basket of 10-15 companies
- Stocks selected based on fundamentals, short term triggers, events, results, and news flows
- Regular review and performance update







Sector View

Sector	View
Automobiles	UW
Banks-Private	UW
Banks-PSU	OW
Capital Goods	OW
Cement	UW
Chemicals	N
Consumer	UW
EMS	N
Healthcare	OW
Infrastructure	OW
Insurance	N
Logistics	N

Sector	View
Media	N
Metals	UW
NBFC	OW
Oil & Gas	UW
Others	N
Real Estate	UW
Retail	UW
Staffing	N
Technology	N
Telecom	OW
Utilities	UW

OW: Overweight; **N:** Neutral; **UW:** Underweight





Performance

Portfolio Performance

	1m	3m	6m	Since inception*
MOSt Signature	6.2%	-16.7%	-15.7%	-4.1%
Nifty 200	2.7%	-5.4%	-9.4%	2.2%

^{*} Inception date: 10-May-2024

Returns are post expenses and includes dividends

Last few exits

Scrip Name	Buy Price	Sell Price	Gain/Loss
DIVISLAB	4,499	5,483	22%
TATASTEEL	151	140	-7%
COFORGE	7,525	6,608	-12%
HCLTECH	1,838	1,550	-16%
LODHA	1401.35	1075	-23%

Last 5 entries

Scrip Name	Buy Price	Allocation
AMBER	6,375	5%
VBL	481	5%
CASTROLIND	203	5%
HINDPETRO	358.35	5%
POWERGRID	293.9	5%

Price performance of Recommendations

Portfolio				
Scrip Name	Weight	Reco Price	Price (4th April'25)	Gain/Loss
ICICIBANK	5%	1,118	1,335	19%
INDIGO	5%	4,395	5,099	16%
VBL	5%	481	535	11%
DIVISLAB	5%	4,991	5,483	10%
TATACONSUM	5%	1,023	1,088	6%
ZOMATO	5%	204	211	3%
CASTROLIND 🛨	5%	203	203	0%
HINDPETRO 🛨	5%	358	358	0%
POWERGRID 🛨	5%	294	294	0%
KAYNES	5%	4,353	4,650	7%
JKCEMENT	5%	4,898	4,955	1%
SHRIRAMFIN	5%	625	654	5%
AMBER	5%	6,375	6,595	3%
MANKIND	5%	2,562	2,451	-4%
LT	5%	3,277	3,260	-1%
MAXHEALTH	5%	1,198	1,138	-5%
INDHOTEL	5%	852	799	-6%
M&M	5%	3,109	2,597	-16%
CAMS	5%	5,212	3,683	-29%
ANANTRAJ	5%	885	457	-48%

[#] Absolute returns as on -4 April-2025





Model Portfolio Recommendation

Portfolio				
Sector	Stocks	Weight	Market Cap	CMP (4 th Apr'25)
	ICICIBANK	5%	Large Cap	1,335
Banking & Finance	SHRIRAMFIN	5%	Large Cap	654
	CAMS	5%	Mid Cap	3,683
Automobile	M&M	5%	Large Cap	2,597
	DIVISLAB	5%	Large Cap	5,483
Healthcare	MANKIND	5%	Large Cap	2,451
	M <mark>axhealth</mark>	5%	Large Cap	1,138
	LT	5%	Large Cap	3,260
Industrials	KAYNES	5%	Mid Cap	4,650
	J <mark>KCEMENT</mark>	5%	Mid Cap	4,955
	TA <mark>T</mark> ACONSUM	5%	Large Cap	1,088
Consumption	VBL	5%	Large Cap	535
	AMBER	5%	Mid Cap	6,595
Oil C Care	CASTROLIND	5%	Mid Cap	203
Oil & Gas	HINDPETRO	5%	Mid Cap	358
Digital	ZOMATO	5%	Large Cap	211
Utilities	POWERGRID	5%	Large Cap	294
Real Estate	ANANTRAJ	5%	Mid Cap	457
Tourism	INDHOTEL	5%	Large Cap	799
	INDIGO	5%	Large Cap	5,099
Total		100%		


★ Denotes New Entry








Sector and Market cap Allocation











earnings beat

Key Rationales

- Sustained ~17% loan CAGR (FY22-24) across Retail, BB, analytics optimizing customer acquisition and risk assessment. Strong asset quality with PCR of ~79% and INR 131b contingency buffer, mitigating risks from rising unsecured loan delinquencies; credit costs expected to normalize to 40-50bp by FY27E.
- NIM stabilization anticipated at 4.25% despite margin compression, supported by digital-led deposit growth outpacing industry averages despite CASA ratio dip to 40.5% in 3QFY25.
- Fee income dominance from Retail/BB (78% share) and controlled cost-to-income ratio (~39%) enhance profitability, complementing loan growth. We expect RoA/RoE of 2.2%/17% by FY27E.

Key Rationales


- SHFL offers a well-diversified product suite and has emerged as a strong player across all its product segments. It has demonstrated strong execution capabilities and asset quality resilience while navigating multiple credit/ economic cycles.
- With diversified lending portfolio, it is set to benefit from lower borrowing costs, which will enhance NIMs & profitability and helped mitigate CV business cyclicality. SHFL is yet to fully tap its expanded distribution network (from the merger) to offer a much wider product bouquet to its customers.
- For 4QFY25, we estimate disbursements of ₹453B and AUM at ₹2.65T (up 18% YoY), with stable credit cost at 2.2%. We expect 18%/19% AUM/PAT CAGR over FY24-27.

Key Rationales

- Structural tailwinds in the MF industry are expected to drive absolute growth in MF revenue. Though AUM has dipped recently due to MTM hit on MFs and weak net flows in near term.
- Non-MF business revenue traction remained strong led by robust products such as CAMSPay, KRA and AIF. With favorable macro triggers and the right investments, revenue contribution from Non-MF businesses for CAMS is expected to increase to 20%+ over the next 2-3 years, as guided by management.
- Recent correction gives an opportunity to buy given its duopoly nature, high entry barriers, low risk of mkt. share loss and high customer ownership.
- We expect revenue/PAT CAGR of 18%/23% over FY24-27E but factor in near-term yield compression.



Building blocks; outperformance to sustain



sustain







earnings beat

Key Rationales

- Zomato's food delivery business remains stable, while Blinkit represents a transformative opportunity to disrupt industries like retail, grocery, and e-commerce.
- Notwithstanding the current slowdown in food delivery, management is positive about a recovery soon and remains confident of its long-term outlook of 20%+ yearly GOV growth given the strong fundamentals.
- Recent correction, led by near-term pressure due to QC expansion & increased marketing spends gives an opportunity to add considering resilient business model & robust capabilities to gain market share in long term.
- Zomato is well-positioned to capitalize on expanding its customer base, increasing order volumes and values, and enhancing unit economics and profitability over the long term. It is expected to achieve PAT margins of 3.5%/6.8%/9.9% in FY25E/FY26E/FY27E, respectively.



outperformance to

sustain

- Early monsoon season due to La Nina effect augurs well for M&M, driven by increased tractor demand. M&M, being a leader in automotive and farm equipment, benefits from strong rural demand & new product launches.
- MM seems to be the best placed among OEMs as both its core underlying segments, SUVs and tractors, outpaced peers. It has reported volume growth of 15% YoY in Mar'25, led by 23%/18% YoY growth in tractors/automotive.
- The budget's focus on electric vehicles (EVs) supports M&M's EV initiatives, while increased agri spending & rural push could drive tractor demand, benefiting its farm equipment seg. We estimate M&M to post a ~13%/16%/15.5% CAGR in revenue/EBITDA/PAT over FY24-27E.







earnings beat

Key Rationales

- DIVI has the skill set across building blocks, fragments, and the polymer level for peptides. It has the capability for solid as well as liquid phase synthesis, thereby providing multiple service offerings to innovator customers.
- Divi's is targeting growth-driven CS segments like peptides & contrast media, where product complexity plays to its strengths. With its proven capabilities, the company is ideally placed to gain a competitive edge and maximize commercial success in these areas.
- We estimate 25% earnings CAGR over FY25-27, driven by improved capacity utilization and healthy traction across key segments.

- Mankind's focus on a differentiated portfolio, comprising: a) prescription products (including the recently acquired BSV), b) consumer wellness, and c) exports, positions the company for robust growth over the next 4-5 years.
- Mankind expects single-digit revenue growth for BSV in FY25, followed by 15%+ growth in FY26 with margins of 26-28%. Over the next 2-3 years, margins are projected to reach ~30%.
- We expect a 20% earnings CAGR over FY25-27, supported by its strong focus on chronic therapies (niche) and exports.



- MAXH is well-positioned as a leading multi-specialty hospital chain, with plans to add 3,600+ beds over 3-4 years through brownfield expansion and strategic acquisitions.
- The Jaypee Hospital acquisition boosts its North India presence, while rising insurance coverage, PPPs, and medical infra investments support long-term growth.
- For 4QFY25, we expect strong 26% YoY revenue growth, aided by volume expansion and 42% YoY growth in Max Labs, with improving margins. Lower ARPOB of ₹73.8K reflects scale-driven growth; ramp-up of Lucknow, Nagpur, and Jaypee units to enhance profitability and reach. We expect a 17% revenue CAGR over FY25-27.



Building blocks; outperformance to sustain



Building blocks; outperformance to sustain







earnings beat

Key Rationales

- LT expects 15%+ revenue growth in Q4FY25, supported by infrastructure, renewables, and new ventures (green hydrogen, data centers, semiconductors). Working capital remains stable, and execution is set to accelerate in key Middle East projects.
- LT bagged an ultra-mega order from QatarEnergy for setting up two offshore compression complexes, likely to be worth USD4b. Orders worth INR~670b were announced during Q4FY25.
- We maintain a BUY rating, supported by a strong order pipeline, revenue visibility and timely execution capability.



Building blocks; outperformance to sustain

TECHNOLOGY

Key Rationales

- KAYNES is expanding into North America, Europe, and South Asia, focusing on ODM and high-margin businesses. Capex of INR23b for semiconductor projects is supported by government subsidies.
- Orders from industrials, EVs, aerospace, and automotive sectors are expected to materialize from FY26. Smart Meters, Railways, and Semiconductor projects (OSAT, HDIPCB) are key growth drivers, with significant revenue contributions from FY26 onwards.
- With a projected 56%/62%/68% CAGR in revenue/EBITDA/PAT over FY24-27, we reiterate BUY, citing margin expansion led by increased traction in high-margin verticals.



outperformance to sustain

- Management expects volume growth of 7-8% in 4QFY25 and ~10% in FY26. In FY25, JKCE will realize cost savings of INR40-50/t and the rest of INR75/t will be realized over the next few quarters.
- Premium product sales were at 16% (highest ever) vs. 14% in 2QFY25. The target is to raise premium products' share to 20%+ in the next two years. Consistently added cement capacity in the last 5 years at CAGR of 18% and will further increase by 25% in FY26 along with various cost savings strategies.
- We expect its revenue/EBITDA/profits to post a CAGR of 9%/12%/18% over FY24-27. We estimate EBITDA/t to reach INR1,149 in FY27 vs. INR1,079 in FY24 and INR953 in FY25. Net debt/EBITDA should reach 1.5x in FY27 vs. 2.2x in FY25F.







Steady quarter; robust other income drives earnings beat



Building blocks; outperformance to sustain



Building blocks; outperformance to sustain

Key Rationales

- TCPL is well-placed for margin recovery, aided by calibrated price hikes in tea and salt, and synergy benefits from Capital Foods and Organic India acquisitions.
- International businesses remain strong profit contributors, supported by structural margin gains in the US, UK, and Canada. Strong growth across Ecommerce (up 59% YoY) and Modern Trade channels enhances visibility.
- For 4QFY25, we expect ~17% YoY revenue growth, led by strong domestic performance, higher tea prices, and sustained volume growth. Salt to post another strong quarter; despite margin normalization (~12.9%), outlook remains robust with estimated 10%/9%/13% CAGR in revenue/EBITDA/PAT over FY24-27.

Key Rationales

- Despite facing short-term headwinds from unfavorable weather and weakened consumption trends, VBL achieved ~12%/23% YoY volume growth in the domestic market/consolidated basis, driven by deeper market penetration.
- VBL is also strategically expanding into the food snacking market, which has the potential to become a key long-term growth driver. For IQCY25, we expect 29% YoY volume growth and stable EBITDA margins, supported by rural refrigeration, wider distribution, seasonal strength.
- With 18%/16%/27% revenue/EBITDA/PAT CAGR expected over CY24–26, expansion-led growth and recent stock correction make the risk-reward favourable.

- IndiGo is well-positioned to capitalize on India's aviation boom, driven by rising middle-class demand, infrastructure investments, and global expansion.
- With a record fleet order of 925 aircraft, including A321 XLR and A350 models, IndiGo aims to double its size by CY30, targeting 600+ aircraft and 200m passengers annually. Its focus on international growth, operational efficiency, and diversified revenue streams (e.g., IndiGo Stretch, BluChip) supports strong profitability.
- Mgmt. continuous efforts to boost global presence via partnerships, loyalty programs, and expanded fleet, targets to increase international market share. Also, domestic strategic initiatives and financial resilience make it a key player in India's aviation growth story.







Steady quarter; robust other income drives earnings beat

Key Rationales

- Management remains bullish on India's lubricant demand, given India's low car penetration, targeting above-industry growth (4-5%) and a 22-25% EBITDA margin.
- Castrol delivered a strong 4QCY24, with EBITDA beating estimates by 25% at INR3.8b, driven by a robust margin of 27.8%. Revenue grew 7% YoY to INR13.5b, while PAT rose 12% YoY to INR2.7b.
- CSTRL's focus on brand building, distribution expansion, and new product launches supports its market leadership. We maintain a BUY (26x CY25E EPS), reflecting confidence in its profitability and growth trajectory.

Key Rationales

- Oil price decline due to OPEC+ output hike and US tariffs is likely to improve HPCL's gross marketing margins, helping offset ₹76b LPG under-recoveries.
- Key triggers include the demerger and potential listing of the lubricant business, commissioning of the bottom upgrade unit in Q4FY25, and Rajasthan refinery launch in CY25.
- 4Q Expectations: Refining throughput at 6.6mmt (+14% YoY), marketing sales volume at 12.5mmt (+1% YoY), reported GRM at USD5.5/bbl, and gross marketing margin at ₹4.6/lit. With expected FY26 RoE of 17%, current valuations look attractive.



Building blocks; outperformance to sustain

- Power Grid remains well-positioned for long-term growth, backed by a robust order book (~₹1.43T), rising capex (₹280-300B guided for FY26), and strong execution capabilities.
- Higher capital expenditure may moderate near-term dividends, the company's leadership in transmission and strategic focus on renewable energy integration (500GW non-fossil target) support sustained growth.
- The company continues to secure key projects, expand its cust. base, and innovate through green initiatives and digital upgrades. With a strong project pipeline, it is well-positioned to capitalize on the multiyear transmission capex upcycle. Stock's valuation remains attractive given its growth trajectory. Reiterate BUY.



Building blocks; outperformance to sustain







earnings beat

Key Rationales

- Amber, a leading RAC and components manufacturer, is seeing strong demand across RAC and EMS segments, supported by new client additions and domestic manufacturing tailwinds.
- It is scaling its EMS capabilities via a ₹6.5B investment in Ascent Circuits and a PLI-linked JV with Korea Circuit. Key monitorables include EMS margin trajectory, demand in RAC/non-RAC segments, and progress in the railway electronics segment.
- For 4QFY25, we expect revenue to grow 10% YoY and PAT to rise 37% YoY, with EBITDA margin expanding 20bp YoY to 8.1%. We estimate a revenue/EBITDA/PAT CAGR of 26%/33%/62% over FY24-27

Key Rationales

- ARCP's residential segment is expected to deliver 14msf over FY25-30, generating a cumulative NOPAT of INR75.3b.
- ARCP is transforming three tech parks into cuttingedge DCs, targeting 300MW capacity over 4-5 years.
 DC revenue is projected to grow from 6MW in FY24 to 307MW by FY32, with cloud services expanding to 77MW, driving EBITDA margins to 77% by FY30.
- It's shift to Data Centre leverages India's digital transformation & data localization trends. Reiterate buy, reflecting growth in DC & residential segments.



Building blocks; outperformance to sustain



Building blocks; outperformance to sustain

- IH expects double-digit revenue growth in FY25, supported by strong demand across weddings, tourism, and MICE segments. ARR and occupancy remain healthy, reflecting strong pricing power across key markets.
- Over 2,800 rooms are planned across spiritual tourism hubs like Ayodhya, Hampi, and Vrindavan, aligning with government efforts to promote tourism.
- FY25 revenue/EBITDA/adj. PAT are expected to grow 31%/34%/26% YoY; 4QFY25 revenue may rise 28% YoY with ~35.1% EBITDA margin. Key cities (Mumbai, Delhi, Hyderabad, Bengaluru) are seeing sustained demand momentum.





The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilalo Securities & Exchange Board of India (SEB) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSÉ) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(jes), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- b) $managed\ or\ co-managed\ public\ offering\ of\ securities\ from\ subject\ company\ of\ this\ research\ report,$
- c)
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d)
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or $indirectly \, related \, to \, the \, specific \, recommendations \, and \, views \, expressed \, by \, research \, analyst(s) \, in \, this \, report.$

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com, Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their view

Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or $which would subject \, \texttt{MOFSL} \, \& \, its \, group \, companies \, to \, registration \, or \, licensing \, requirements \, within \, such \, jurisdictions \, its \, content in a content of the content in the content of the con$

Mr. Ajay Menon

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 57) of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motifal Oswal Financial Services Limited (SEBI Rep No. INH000000412) has an agreement with Motifal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act*) and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is for distribution only to "Major institutional investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). $Any \ business \ interaction \ pursuant \ to \ this \ report \ will \ have \ to \ be \ executed \ within \ the \ provisions \ of \ this \ chaperoning \ agreement.$

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 2011294012) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is $not \ or \ ceases \ to \ be \ such \ an \ institutional \ investor, such \ Singapore \ Person \ must \ immediately \ discontinue \ any \ use \ of \ this \ Report \ and \ inform \ MOCMSPL$

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an nt evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be's uffered by the person accessing this information due to any errors and delays.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No: 022-40548085.

Grievance Redressal Cell: Email ID 022 40548000 / 022 67490600 Ms. Hemanai Date query@motilaloswal.com Ms. Kumud Upadhyay servicehead@motilaloswal.com 022 40548082

022 40548083

Registration details of group entities: Motifal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015: Research Analyst: INH000000412, AMFI; ARN.: 146872. IRDA Corporate Agent -CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

am@motilaloswal.com